Urodynamic effects of silodosin, a new α<sub>1A</sub>‐adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia

Yamanishi, Tomonori; Mizuno, Tomoya; Tatsumiya, Katsuhisa; Watanabe, Miho; Kamai, Takao; Yoshida, Keisuke

doi:10.1002/nau.20802

Cited by 51 publications

(56 citation statements)

References 27 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This primary endpoint was considered sufficient to show clinical efficacy. 6,8,12,14,15 To allow patients to make a fair evaluation of the drugs, a crossover design in which patients were treated with both drugs in consecutive 4-week periods, was applied.…”

Section: Discussionmentioning

confidence: 99%

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Watanabe

Ozono

Kageyama³

2011

J Int Med Res

View full text Add to dashboard Cite

Patient preference for benign prostatic hyperplasia (BPH) treatment with the a 1 -blockers, tamsulosin or silodosin, was compared using patient-reported outcomes. Japanese patients with lower urinary tract symptoms associated with BPH were randomly allocated to either the T-S group (tamsulosin 0.2 mg orally once daily for 4 weeks then silodosin 4 mg orally twice daily for 4 weeks) or the S-T group (silodosin 4 mg orally twice daily for 4 weeks then tamsulosin 0.2 mg orally once daily for 4 weeks).

show abstract

Section: Discussionmentioning

confidence: 99%

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Watanabe

Ozono

Kageyama³

2011

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…Furthermore, Silodosin is highly bound to serum proteins, and its displacement from protein binding sites may occur when is coadministrated with other highly protein bound drugs, like VA: this interaction is another mechanism that can lead to the increase of Silodosin serum concentration [29,30] (Figure 4). In our case, we acknowledge that itching skin rash is due to the interaction between VA and Silodosin, since the presentation of the ADR appeared after the introduction of Silodosin and stopped as soon as VA treatment was discontinued, without any recurrence.…”

Section: Discussionmentioning

confidence: 99%

Itching Skin Rash during Valproic Acid Therapy in Co-Administration with Silodosin: a Case Report and Review of Literature

Romano¹,

Marino²

2016

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Valproic acid (VA) is an antiepileptic drug commonly used in psychiatric setting as mood stabilizer. It is generally well-tolerated but, because of its pharmacodynamic properties, it may cause different adverse drug reactions, especially when it is co-administrated with other drugs.Here we report the case of a 65 year old man with a Bipolar Disorder type I, according to DSM V, hospitalized for a depressive relapse and treated with Valproic Acid 300 mg/day, Lorazepam 2.5 mg/day, and Elopram 40 mg/ml intravenous daily infusions. When, one week after admission, Silodosin 8 mg/day was added for the management of Benign Prostatic Hyperplasia (BPH) symptoms, he developed an extensive pruritic and purpuric skin rash on his lower legs that subsided after valproic acid discontinuation and therapy with intravenous fluids and oral antihistamines. Therefore, valproic acid was replaced with Pregabalin, which was well tolerated by the patient who recovered quickly.Our clinical experience and the pharmacologic mechanisms underlying the onset of this adverse drug reaction are discussed in detail. Since valproic acid inhibits the uridin-glucuronyl transferase-2B7 (UGT2B7) enzyme that is involved in the metabolism of silodosin, a likely interaction between valproic acid and silodosin elimination pathway has been considered as a possible precipitating factor in our case. The goal of this case report is to draw clinicians' attention on the significant risk of pharmacokinetic interaction in patients undergoing multiple treatments for different diseases.

show abstract

“…Neither of these studies showed a significant increase in Qmax, and this was attributed to a particularly high placebo response. However, an open-label study to investigate the urodynamic effects of silodosin in 36 men revealed a statistically significant increase in Qmax after 1 to 12 months of therapy and an improvement in obstruction grade in 56% of men [25]. Maximum cystometric capacity also increased compared to baseline and detrusor overactivity disappeared in 40% of men, with improvement in a further 35%.…”

Section: Emerging Treatmentsmentioning

confidence: 98%

Emerging Treatment Options for Benign Prostatic Obstruction

Parsons

Hashim

2011

Curr Urol Rep

View full text Add to dashboard Cite

Benign prostatic obstruction (BPO) affects an increasing number of men with age. It can cause troublesome lower urinary tract symptoms, can have a negative impact on quality of life, and may be associated with significant morbidity. Currently available medication and surgical treatments are limited by adverse events, invasiveness, and patient compliance. This has driven research into the pathogenesis of benign prostatic hyperplasia and led to the development of novel pharmacological agents and minimally invasive therapeutic interventions. This review highlights emerging treatment options for BPO.

show abstract

Urodynamic effects of silodosin, a new α_1A‐adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia

Abstract: Silodosin appears to improve detrusor overactivity and obstruction grade in patients with BPH. With silodosin treatment, LUTS could be managed effectively for more than a year in at least 44% of the patients.

Cited by 51 publications

References 27 publications

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Itching Skin Rash during Valproic Acid Therapy in Co-Administration with Silodosin: a Case Report and Review of Literature

Emerging Treatment Options for Benign Prostatic Obstruction

Contact Info

Product

Resources

About

Urodynamic effects of silodosin, a new α1A‐adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia

Abstract: Silodosin appears to improve detrusor overactivity and obstruction grade in patients with BPH. With silodosin treatment, LUTS could be managed effectively for more than a year in at least 44% of the patients.

Cited by 51 publications

References 27 publications

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

A Randomized Crossover Study Comparing Patient Preference for Tamsulosin and Silodosin in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Itching Skin Rash during Valproic Acid Therapy in Co-Administration with Silodosin: a Case Report and Review of Literature

Emerging Treatment Options for Benign Prostatic Obstruction

Contact Info

Product

Resources

About

Urodynamic effects of silodosin, a new α_1A‐adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia